Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Gwo Fuang Ho's publication output changed over time?
ScholarIQpublication output · 2014–2023
Output grew0% over the shown period — from 1 works in 2014 to 1 in 2023.
1
1
1
1
2
1
3
1
20142016201720182019202020222023
What are the most-cited papers on Gwo Fuang Ho?
ScholarIQmost cited works
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
L.-T. Chen, Erika Martinelli, Ann‐Lii Cheng, George Pentheroudakis, Si-bei Qin, G.S. Bhattacharyya, Masafumi Ikeda, Ho Yeong Lim, Gwo Fuang Ho, Su Pin Choo, Zhenggang Ren, Hemant Malhotra, Makoto Ueno, Baek‐Yeol Ryoo, Tina Kiang, David Tai, Arndt Vogel, Andrés Cervantes, Sheng‐Nan Lu, Chung‐Jen Yen, Yi‐Hsiang Huang, San‐Chi Chen, Chiun Hsu, Ying‐Chun Shen, Josep Tabernero, Yun Yen, Chih‐Hung Hsu, Takayuki Yoshino, J.-Y. Douillard
Annals of Oncology. 2020243 Citations
Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial
Shukui Qin, Zhendong Chen, Weijia Fang, Zhenggang Ren, Ruocai Xu, Baek‐Yeol Ryoo, Zhiqiang Meng, Yuxian Bai, Xiaoming Chen, Xiufeng Liu, Juxiang Xiao, Gwo Fuang Ho, Yimin Mao, Xin Wang, Jieer Ying, Jianfeng Li, Wenyan Zhong, Yu Zhou, Abby B. Siegel, Chunyi Hao
Journal of Clinical Oncology. 2022191 CitationsOPEN ACCESS
Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non‐small cell lung cancer or colorectal cancer: a randomized, double‐blind, placebo‐controlled, international multicentre phase II study (the ACT‐ONE trial)
Andrew J.S. Coats, Gwo Fuang Ho, Kumar Prabhash, Stephan von Haehling, Julia Tilson, R. H. Brown, John Beadle, Stefan D. Anker, for and on behalf of the ACT‐ONE study group
S173726759. 2016173 CitationsOPEN ACCESS
Treatment of Patients With Early-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline
Ainhoa Costas‐Chavarri, Govind Nandakumar, Sarah Temin, Gilberto Lopes, Andrés Cervantes, Marcia Cruz Correa, R. Engineer, Chisato Hamashima, Gwo Fuang Ho, Fidel David Huitzil, Mona Malekzadeh, Ala I. Sharara, Mariana C. Stern, Catherine Teh, Sara E. Vázquez Manjarrez, Azmina Verjee, Rhonda K. Yantiss, Manish A. Shah
S2764879405. 2019157 CitationsOPEN ACCESS
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial
Anthony T.�C. Chan, V.H.F. Lee, R-L. Hong, M-J. Ahn, Wan Qin Chong, S. B. Kim, Gwo Fuang Ho, Priscilla B. Caguioa, Nuttapong Ngamphaiboon, Cheryl Ho, Mubashir Aziz, Quan Sing Ng, C-J. Yen, Nopadol Soparattanapaisarn, Roger KC Ngan, S.K. Kho, M.L.A. Tiambeng, Tak Yun, Virote Sriuranpong, Alain P. Algazi, Andy S. K. Cheng, Erminia Massarelli, Ramona F. Swaby, Sanatan Saraf, Jianda Yuan, Lillian L. Siu
Annals of Oncology. 2022113 CitationsOPEN ACCESS
Related on ScholarIQ
University Malaya Medical Centre
Institution
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
Paper
Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial
Paper
Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non‐small cell lung cancer or colorectal cancer: a randomized, double‐blind, placebo‐controlled, international multicentre phase II study (the ACT‐ONE trial)
Paper
Treatment of Patients With Early-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline
Paper
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial
Paper